Hyperfine Inc. has announced the enrollment of the first patient in the Contrast PMR study, a prospective, multi-center clinical trial evaluating the feasibility and visualization benefits of using gadolinium-based contrast agents with the Swoop® portable MRI system. The primary objective of the study is to assess the visualization of brain lesions, including those associated with blood-brain barrier disruption, using contrast-enhanced ultra-low-field MRI. Approximately 70 patients will be enrolled across multiple sites in the United States. The results from this study are intended to support a future FDA submission to expand the system’s intended use and are anticipated to be submitted towards the end of 2026. Results from the study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hyperfine Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260115207956) on January 15, 2026, and is solely responsible for the information contained therein.